@Article{or.2026.083206,
AUTHOR = {Krittiya Korphaisarn, Kosin Wirasorn, Suebpong Tanasanvimon, Kijjakom Thanasombunsukh, Kunlatida Maneenil, Jirawat Thanestada, Nattaya Teeyapun, Jarin Chindaprasirt, Chirawadee Sathitruangsak, Teerada Siripoon, Phannin Tiraswasdichai, Chanchai Charonpongsuntorn, Passakorn Wanchaijiraboon, Wannisa Laosuangkoon, Patrapim Sunpaweravong, Ekapop Sirachainan, Charuwan Akewanlop},
TITLE = {Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/27415},
ISSN = {1555-3906},
ABSTRACT = {<b>Introduction:</b> Durvalumab plus tremelimumab (Durva/Treme) improved survival in the HIMALAYA trial for unresectable hepatocellular carcinoma (HCC), but real-world evidence remains limited. This study aimed to evaluate clinical outcomes of Durva/Treme in routine practice. <b>Methods:</b> This retrospective multicenter study included patients with unresectable or advanced HCC who received Durva/Treme through the Expanded Access Program in Thailand between August 2023 and November 2025. Treatment outcomes and adverse events (AEs) were analyzed and descriptively compared with the HIMALAYA trial. <b>Results:</b> Fifty patients were included; median age was 62 years and 80% were male. Etiologies included hepatitis B (44%), hepatitis C (30%), and nonviral liver disease (26%). Most patients had Child–Pugh A (92%), while 24% had macrovascular invasion, including five with Vp4 portal vein involvement. The objective response rate (ORR) and disease control rate (DCR) were 12% and 60%, respectively. Among 43 patients meeting HIMALAYA eligibility criteria, ORR and DCR were 12% and 56%, respectively. With a median follow-up of 28.9 months, median progression-free survival (mPFS) and overall survival (mOS) were 4.6 and 10.5 months in the overall cohort, and 6.9 and 14.0 months in the HIMALAYA-eligible subgroup. Any-grade AEs occurred in 76% of patients, with grade ≥ 3 AEs in 24%. Hepatitis was the most common toxicity (48% overall; 14% grade ≥ 3). <b>Conclusions:</b> Durva/Treme demonstrated clinically meaningful activity with manageable toxicity in unresectable HCC. Outcomes among HIMALAYA-eligible patients were broadly consistent with the pivotal trial, supporting the feasibility of this regimen in routine clinical practice.},
DOI = {10.32604/or.2026.083206}
}